公开(公告)号：US09072698B2

公开(公告)日：2015-07-07

申请号：US13482568

申请日：2012-05-29

Applicant: Ki Hun Park ,  Jung Weon Lee ,  Young Bae Ryu ,  Hyung Won Ryu ,  Sin-Ae Lee

Inventor： Ki Hun Park ,  Jung Weon Lee ,  Young Bae Ryu ,  Hyung Won Ryu ,  Sin-Ae Lee

IPC: C12Q1/00 ,  A61K31/135 ,  C07C49/835 ,  C07C49/84 ,  C07C309/66 ,  C07C309/73 ,  C07C309/75 ,  C07C309/76 ,  C07C311/21 ,  C07C311/29 ,  C07C311/44 ,  G01N33/50

CPC classification number: A61K31/135 ,  C07C49/835 ,  C07C49/84 ,  C07C309/66 ,  C07C309/73 ,  C07C309/75 ,  C07C309/76 ,  C07C311/21 ,  C07C311/29 ,  C07C311/44 ,  G01N33/5011 ,  G01N2333/9121

Abstract: The present invention relates to a method for screening an anticancer compound and an anticancer compound screened using the method, and more particularly, to a method for screening an anticancer compound, the method comprising: culturing cancer cells expressing the oncogenic protein transmembrane 4 L6 family member 5 (TM4SF5), expressed as the polypeptide of SEQ ID NO: 2, treating the cancer cells with an anticancer candidate, and determining that the anticancer candidate is an anticancer substance when the candidate exhibits antagonistic activity against tumor formation and metastasis based on several events through the molecular mechanism of TM4SF5. The present invention also relates to chalcone compounds screened to have anticancer activity using the method, and an anticancer composition comprising the compound as an effective ingredient.

Abstract translation: 本发明涉及使用该方法筛选抗癌化合物和抗癌化合物的方法，更具体地，涉及一种抗癌化合物的筛选方法，所述方法包括：培养表达致癌蛋白跨膜4L6家族成员的癌细胞 5（TM4SF5），表达为SEQ ID NO：2的多肽，用抗癌候选物治疗癌细胞，并且当候选物基于若干事件显示出对肿瘤形成和转移的拮抗活性时，确定抗癌候选物是抗癌物质 通过TM4SF5的分子机制。 本发明还涉及使用该方法筛选具有抗癌活性的查耳酮化合物和包含该化合物作为有效成分的抗癌组合物。

公开(公告)号：US08299049B2

公开(公告)日：2012-10-30

申请号：US12626553

申请日：2009-11-25

Applicant: Hyeong-Kyu Lee ,  Sei-Ryang Oh ,  Kyungseop Ahn ,  Joongku Lee ,  Sangku Lee ,  Ho-Jae Lee ,  Doo-Young Kim ,  Jung-Hee Kim ,  Eun-Ah Kim ,  Soon-Ja Choi ,  Soo Hyun Kim ,  Jung Weon Lee ,  Su-Yong Choi

Inventor： Hyeong-Kyu Lee ,  Sei-Ryang Oh ,  Kyungseop Ahn ,  Joongku Lee ,  Sangku Lee ,  Ho-Jae Lee ,  Doo-Young Kim ,  Jung-Hee Kim ,  Eun-Ah Kim ,  Soon-Ja Choi ,  Soo Hyun Kim ,  Jung Weon Lee ,  Su-Yong Choi

IPC: A61K31/56

CPC classification number: A61K36/185 ,  A23L33/105

Abstract: The present invention relates to an anoikis-inducing agent comprising a Tiarella polyphylla extract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. The Tiarella polyphylla extract, the tiarellic acid compound isolated therefrom or pharmaceutically acceptable salt thereof of the present invention leads to loss of cell adhesion to reduce cancer cell proliferation and exhibits the effect of inducing cell death in cancer cells expressing a tumor-associated antigen L6 or a homolog thereof, thereby being used for preventing and treating cancer diseases due to a tumor-associated antigen L6 or a homolog thereof.

Abstract translation: 本发明涉及一种脱氧诱导剂，其包含与其分离的天竺葵多酚提取物，从其分离的噻托溴酸化合物或其药学上可接受的盐，其对表达肿瘤相关抗原L6的癌细胞或其同源物是特异性的。 本发明的天竺葵多酚提取物，从其分离的噻托溴酸化合物或其药学上可接受的盐导致细胞粘附丧失，以减少癌细胞增殖，并表现出在表达肿瘤相关抗原L6的癌细胞中诱导细胞死亡的作用 其同系物，因此用于预防和治疗由于肿瘤相关抗原L6或其同源物引起的癌症。

公开(公告)号：US09057725B2

公开(公告)日：2015-06-16

申请号：US13813135

申请日：2011-07-22

Applicant: Jung Weon Lee ,  Ki Hun Park ,  Min Kyung Kang

Inventor： Jung Weon Lee ,  Ki Hun Park ,  Min Kyung Kang

IPC: G01N33/563 ,  A61K39/395 ,  A61K39/00 ,  G01N33/68 ,  G01N33/50 ,  A61K31/18

CPC classification number: G01N33/563 ,  A61K31/18 ,  G01N33/5067 ,  G01N33/6893 ,  G01N2800/085

Abstract: A composition for diagnosing, treating, and preventing liver disease, more particularly a composition for diagnosing liver disease comprising a material for measuring the grade of TM4SF5 (transmembrane 4 L six family member 5 or four-transmembrane L6 superfamily member 5) protein, a kit for diagnosing liver disease comprising the composition, a method for providing information necessary for diagnosing liver disease composed of the following steps: measuring the level of TM4SF5 protein and the expressions and phosphorylations of TM4SF5 expression related signaling proteins; and comparing the measured levels with those of the normal control, a method for screening a material for treating liver disease, and a composition for treating or preventing liver disease comprising a material inhibiting TM4SF5 protein expression or the expressions and phosphorylations of TM4SF5 expression related signaling proteins.

Abstract translation: 一种用于诊断，治疗和预防肝病的组合物，更具体地，用于诊断肝病的组合物，包括用于测量TM4SF5等级的材料（跨膜4L六族成员5或四跨膜L6超家族成员5）蛋白质，试剂盒 用于诊断包括该组合物的肝病的方法，提供诊断肝病所必需的信息的方法，其包括以下步骤：测量TM4SF5蛋白的水平以及TM4SF5表达相关信号蛋白的表达和磷酸化; 将所测量的水平与正常对照组相比较，筛选用于治疗肝病的材料的方法，以及用于治疗或预防肝病的组合物，其包括抑制TM4SF5蛋白表达的物质或TM4SF5表达相关信号蛋白的表达和磷酸化 。

公开(公告)号：US08445722B2

公开(公告)日：2013-05-21

申请号：US12162940

申请日：2007-12-07

Applicant: Ki Hun Park ,  Jung Weon Lee ,  Young Bae Ryu ,  Hyung Won Ryu ,  Sin-Ae Lee

Inventor： Ki Hun Park ,  Jung Weon Lee ,  Young Bae Ryu ,  Hyung Won Ryu ,  Sin-Ae Lee

IPC: G01N33/53 ,  C12Q1/48 ,  C12Q1/34 ,  C07C311/00 ,  C07C309/63

CPC classification number: A61K31/135 ,  C07C49/835 ,  C07C49/84 ,  C07C309/66 ,  C07C309/73 ,  C07C309/75 ,  C07C309/76 ,  C07C311/21 ,  C07C311/29 ,  C07C311/44 ,  G01N33/5011 ,  G01N2333/9121

Abstract: The present invention relates to a method for screening an anticancer compound and an anticancer compound screened using the method, and more particularly, to a method for screening an anticancer compound, the method comprising: culturing cancer cells expressing the oncogenic protein transmembrane 4 L6 family member 5 (TM4SF5), expressed as the polypeptide of SEQ ID NO: 2, treating the cancer cells with an anticancer candidate, and determining that the anticancer candidate is an anticancer substance when the candidate exhibits antagonistic activity against tumor formation and metastasis based on several events through the molecular mechanism of TM4SF5. The present invention also relates to chalcone compounds screened to have anticancer activity using the method, and an anticancer composition comprising the compound as an effective ingredient.

公开(公告)号：US20100068730A1

公开(公告)日：2010-03-18

申请号：US12162940

申请日：2007-12-07

Applicant: Ki Hun PARK ,  Jung Weon LEE ,  Young Bae RYU ,  Hyung Won RYU ,  Sin-Ae LEE

Inventor： Ki Hun PARK ,  Jung Weon LEE ,  Young Bae RYU ,  Hyung Won RYU ,  Sin-Ae LEE

IPC: G01N33/53 ,  C12Q1/48 ,  C12Q1/34 ,  C07C311/00 ,  C07C309/63

CPC classification number: A61K31/135 ,  C07C49/835 ,  C07C49/84 ,  C07C309/66 ,  C07C309/73 ,  C07C309/75 ,  C07C309/76 ,  C07C311/21 ,  C07C311/29 ,  C07C311/44 ,  G01N33/5011 ,  G01N2333/9121

Abstract: The present invention relates to a method for screening an anticancer compound and an anticancer compound screened using the method, and more particularly, to a method for screening an anticancer compound, the method comprising: culturing cancer cells expressing the oncogenic protein transmembrane 4 L6 family member 5 (TM4SF5), expressed as the polypeptide of SEQ ID NO: 2, treating the cancer cells with an anticancer candidate, and determining that the anticancer candidate is an anticancer substance when the candidate exhibits antagonistic activity against tumor formation and metastasis based on several events through the molecular mechanism of TM4SF5. The present invention also relates to chalcone compounds screened to have anticancer activity using the method, and an anticancer composition comprising the compound as an effective ingredient.

Abstract translation: 本发明涉及使用该方法筛选抗癌化合物和抗癌化合物的方法，更具体地，涉及一种抗癌化合物的筛选方法，所述方法包括：培养表达致癌蛋白跨膜4L6家族成员的癌细胞 5（TM4SF5），表达为SEQ ID NO：2的多肽，用抗癌候选物治疗癌细胞，并且当候选物基于若干事件显示出对肿瘤形成和转移的拮抗活性时，确定抗癌候选物是抗癌物质 通过TM4SF5的分子机制。 本发明还涉及使用该方法筛选具有抗癌活性的查耳酮化合物和包含该化合物作为有效成分的抗癌组合物。

公开(公告)号：US20120282619A1

公开(公告)日：2012-11-08

申请号：US13482568

申请日：2012-05-29

Applicant: Ki Hun Park ,  Jung Weon Lee ,  Young Bae Ryu ,  Hyung Won Ryu ,  Sin-Ae Lee

Inventor： Ki Hun Park ,  Jung Weon Lee ,  Young Bae Ryu ,  Hyung Won Ryu ,  Sin-Ae Lee

IPC: C12Q1/48 ,  C12Q1/68 ,  C12Q1/02 ,  G01N33/566 ,  G01N33/573 ,  C12Q1/34

CPC classification number: A61K31/135 ,  C07C49/835 ,  C07C49/84 ,  C07C309/66 ,  C07C309/73 ,  C07C309/75 ,  C07C309/76 ,  C07C311/21 ,  C07C311/29 ,  C07C311/44 ,  G01N33/5011 ,  G01N2333/9121

Abstract: The present invention relates to a method for screening an anticancer compound and an anticancer compound screened using the method, and more particularly, to a method for screening an anticancer compound, the method comprising: culturing cancer cells expressing the oncogenic protein transmembrane 4 L6 family member 5 (TM4SF5), expressed as the polypeptide of SEQ ID NO: 2, treating the cancer cells with an anticancer candidate, and determining that the anticancer candidate is an anticancer substance when the candidate exhibits antagonistic activity against tumor formation and metastasis based on several events through the molecular mechanism of TM4SF5. The present invention also relates to chalcone compounds screened to have anticancer activity using the method, and an anticancer composition comprising the compound as an effective ingredient.

Abstract translation: 本发明涉及使用该方法筛选抗癌化合物和抗癌化合物的方法，更具体地，涉及一种抗癌化合物的筛选方法，所述方法包括：培养表达致癌蛋白跨膜4L6家族成员的癌细胞 5（TM4SF5），表达为SEQ ID NO：2的多肽，用抗癌候选物治疗癌细胞，并且当候选物基于若干事件显示出对肿瘤形成和转移的拮抗活性时，确定抗癌候选物是抗癌物质 通过TM4SF5的分子机制。 本发明还涉及使用该方法筛选具有抗癌活性的查耳酮化合物和包含该化合物作为有效成分的抗癌组合物。

公开(公告)号：US20130178533A1

公开(公告)日：2013-07-11

申请号：US13813135

申请日：2011-07-22

Applicant: Jung Weon Lee ,  Ki Hun Park ,  Min Kyung Kang

Inventor： Jung Weon Lee ,  Ki Hun Park ,  Min Kyung Kang

IPC: G01N33/68

CPC classification number: G01N33/563 ,  A61K31/18 ,  G01N33/5067 ,  G01N33/6893 ,  G01N2800/085

Abstract: The present invention relates to a composition for diagnosing, treating, and preventing liver disease, more particularly a composition for diagnosing liver disease comprising a material for measuring the grade of TM4SF5 (transmembrane 4 L six family member 5 or four-transmembrane L6 superfamily member 5) protein, a kit for diagnosing liver disease comprising the said composition, a method for providing information necessary for diagnosing liver disease composed of the following steps; measuring the level of TM4SF5 protein and the expressions and phosphorylations of TM4SF5 expression related signaling proteins; and comparing the measured levels with those of the normal control, a method for screening a material for treating liver disease, and a composition for treating or preventing liver disease comprising a material inhibiting TM4SF5 protein expression or the expressions and phosphorylations of TM4SF5 expression related signaling proteins.

Abstract translation: 本发明涉及用于诊断，治疗和预防肝病的组合物，更具体地，涉及用于诊断肝病的组合物，其包括用于测量TM4SF5等级的材料（跨膜4L六族成员5或四跨膜L6超家族成员5 ）蛋白，用于诊断肝病的试剂盒，其包含所述组合物，提供用于诊断由以下步骤组成的肝病所需的信息的方法; 测量TM4SF5蛋白的水平以及TM4SF5表达相关信号蛋白的表达和磷酸化; 将所测量的水平与正常对照组相比较，筛选用于治疗肝病的材料的方法，以及用于治疗或预防肝病的组合物，其包括抑制TM4SF5蛋白表达的物质或TM4SF5表达相关信号蛋白的表达和磷酸化 。

公开(公告)号：US20100081638A1

公开(公告)日：2010-04-01

申请号：US12626553

申请日：2009-11-25

Applicant: Hyeong-Kyu Lee ,  Sei-Ryang Oh ,  Kyungseop Ahn ,  Joongku Lee ,  Sangku Lee ,  Ho-Jae Lee ,  Doo-Young Kim ,  Jung-Hee Kim ,  Eun-Ah Kim ,  Soon-Ja Choi ,  Soo Hyun Kim ,  Jung Weon Lee ,  Su-Yong Choi

Inventor： Hyeong-Kyu Lee ,  Sei-Ryang Oh ,  Kyungseop Ahn ,  Joongku Lee ,  Sangku Lee ,  Ho-Jae Lee ,  Doo-Young Kim ,  Jung-Hee Kim ,  Eun-Ah Kim ,  Soon-Ja Choi ,  Soo Hyun Kim ,  Jung Weon Lee ,  Su-Yong Choi

IPC: A61K31/56 ,  C07J53/00

CPC classification number: A61K36/185 ,  A23L33/105

Abstract: The present invention relates to an anoikis-inducing agent comprising a Tiarella polyphylla extract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. The Tiarella polyphylla extract, the tiarellic acid compound isolated therefrom or pharmaceutically acceptable salt thereof of the present invention leads to loss of cell adhesion to reduce cancer cell proliferation and exhibits the effect of inducing cell death in cancer cells expressing a tumor-associated antigen L6 or a homolog thereof, thereby being used for preventing and treating cancer diseases due to a tumor-associated antigen L6 or a homolog thereof.

Abstract translation: 本发明涉及一种脱氧诱导剂，其包含与其分离的天竺葵多酚提取物，从其分离的噻托溴酸化合物或其药学上可接受的盐，其对表达肿瘤相关抗原L6的癌细胞或其同源物是特异性的。 本发明的天竺葵多酚提取物，从其分离的噻托溴酸化合物或其药学上可接受的盐导致细胞粘附丧失，以减少癌细胞增殖，并表现出在表达肿瘤相关抗原L6的癌细胞中诱导细胞死亡的作用 其同系物，因此用于预防和治疗由于肿瘤相关抗原L6或其同源物引起的癌症。